1 TITLE

Dolutegravir-related hyperglycemia among children and adolescents <18 years in Northern and
Eastern Uganda: A cross-sectional study
Authors: Fridah Akello ^{1*} , Damalie Nalwanga ^{1,3} Victor Musiime ^{1, 2} , Sarah Kiguli ¹ Institutions:
1. Department of Paediatrics and Child Health, School of Medicine, College of Health Sciences,
Makerere University, P.O.Box, 7072, Kampala, Uganda.
2. Joint Clinical Research Center, Kampala, Uganda
3. Makerere Lung Institute, Kampala, Uganda
* Corresponding author email address: fridah.akello@gmail.com

15

ABSTRACT

16	Background: The World Health Organization (WHO) recommended Dolutegravir (DTG) as the
17	preferred anchor drug for first and second line Anti-Retroviral Treatment (ART) regimen. Case
18	reports and studies have demonstrated new onset hyperglycemia among adults initiated or
19	transitioned to DTG. There is paucity of data on DTG-related hyperglycemia among children and
20	adolescents and subsequently, glycemic screening is not routinely conducted for those using
21	DTG. We determined the prevalence and factors associated with DTG-related hyperglycemia in
22	this age category.
23	Methods: This cross-sectional study was conducted from 28th October 2022 to 11th September
24	2023 at Soroti and Lira Regional Referral Hospitals. 251 children and adolescents under 18
25	years, on a DTG based ART regimen, were consecutively enrolled and data analyzed for 240
26	participants. Socio-demographic, anthropometric measurements, clinical, and laboratory
27	variables were collected using a questionnaire. Random blood glucose testing, urine dipstick and
28	HbA1c analyses were conducted. Data was entered into epiData version 4.6, cleaned, and
29	analyzed using STATA version 17.0. Logistic regression was used to determine the relationship
30	between outcome and predictor variables. A p-value < 0.05 was considered statistically
31	significant at multivariate analysis.
32	Results: Of the 240 study participants, 55.4 %(n=133) were female and 71.7 %(n =172) were
33	over 10 years. The prevalence of DTG-related-hyperglycemia was 20% (n=49) and 95.9%
34	(n=47) met the criteria for pre-diabetes. Health education talks on Adverse events related to
35	Dolutegravir was protective for hyperglycemia (aOR 0.4, 95% CI 0.2-0.9), $p = 0.035$.
36	Conclusion: The prevalence of DTG-related-hyperglycemia was high, occurring in every 2 in 10
37	children and adolescents. Health education talks on adverse events associated with DTG use

38	were found to be protective against hyperglycemia. Routine glycemic screening and monitoring
39	therefore should be emphasized. Additionally, a strategy for health education talks focusing on
40	lifestyle modifications to reduce the occurrence of hyperglycemia should be developed.
41	Key words: Hyperglycemia, Dolutegravir
42	
43	
44	
45	
46	
47	
48	
49	
50	
51	
52	
53	
54	
55	
56	
57	
58	
59	
	2
	3

60

61 Introduction

62	The world Health Organization and Ministry of Health recommended Dolutegravir (DTG), an
63	Integrase Strand Transfer Inhibitor (INSTI) as the preferred anchor drug for first and second line
64	HIV treatment options (1). This was supported by study results from the ODYSSEY (Once-daily
65	Dolutegravir based ART in Young people versus Standard Therapy) and Penta-17 trials that
66	showed Dolutegravir to be superior to the current standard of care ART regimen (predominantly
67	a Protease Inhibitor based-ART) in children and adolescents (2).
68	Subsequently, all eligible persons living with HIV are being initiated or optimized to a DTG
69	containing regimen however, a number of case reports and studies among adult patients
70	document symptomatic hyperglycemia associated with initiation on DTG (3-5). Hyperglycemia
71	is defined as a fasting blood glucose level of >7.0 mmol/L or a random plasma glucose greater
72	than 11.1 mmol/L and or an HBA1C level >6.5%(6). The prediabetes state defined by the
73	American Diabetic association as a state of intermediate hyperglycemia based on blood glucose
74	levels or estimates of glycated haemoglobin levels is also considered hyperglycemia.
75	DTG is postulated to cause hyperglycemia through chelation of magnesium to prevent HIV from
76	integrating into host DNA(7,8). Because magnesium serves as a cofactor in post-receptor insulin
77	action, Magnesium chelation may cause disorders of glucose metabolism (9,10). In addition,
78	concomitant HIV infection is associated with insulin resistance resulting from immune activation
79	and chronic inflammation thus worsening the hyperglycemia (11).
80	Despite these isolated study findings, there is paucity of data on DTG associated hyperglycemia
81	and even more particularly in the pediatric and adolescent population. Hyperglycemia if
82	undetected or managed late poses severe acute complications including Diabetic Ketoacidosis

83 (DKA) and Hyperosmolar Hyperglycemic State (HHS) (12). Chronic complications are related 84 to the micro vascular changes which predispose to retinopathy, nephropathy and neuropathy 85 resulting from cellular damage inflicted by the hyperglycemia (13). 86 Ministry of Health (MoH) Uganda HIV treatment guidelines (2022) recommend routine 87 monitoring for therapeutic response and drug related adverse events for all children and 88 adolescents on ART however glycemic monitoring is not specifically mentioned. In contrast 89 however, baseline random blood sugar testing and routine monitoring for adults over 45 years is 90 emphasized in these treatment guidelines. (14). Furthermore, there is scanty data on prevalence 91 and factors associated with DTG-related-hyperglycemia among children and adolescents in 92 Uganda and this study addressed this knowledge gap. Findings from this study form a point of 93 reference for additional studies and guidelines to improve adverse events monitoring for children 94 and adolescents on DTG.

95 Methods

96 Study site

97 This was conducted at the HIV clinics of Soroti and Lira Regional Referral Hospitals (RRHs) 98 both tertiary level health care facilities in Eastern and Northern Uganda respectively. Soroti RRH 99 was the primary study site and Lira RRH was included as an additional site having reached 100 saturation in Soroti. Lira RRH was chosen owing to its homogeneity to Soroti in regard to 101 dietary and activity characteristics of the population. Both regions were ravaged by the 5 year 102 LRA war in 2002-2006 and resultantly bore the brunt of the HIV epidemic with relatively high 103 rates of HIV transmission. Each of the hospitals has one of the largest pediatric HIV enrollments 104 in the respective regions and subsequently, a high number of children and adolescents on a DTG 105 based ART regimen. Soroti RRH serves a catchment area with a population of 2.7 million

- 106 persons. Lira RRH on the other hand offers general and specialized health care services to a
- 107 population of close to 2.3 million individuals from the 9 districts of Lango sub-region.
- 108 Study population and sample size determination
- 109 These were all children and adolescents below 18 years on a DTG containing regimen for at least
- 110 6 months attending the paediatric HIV clinics of Soroti and Lira RRHs. The study was conducted
- 111 from 28th October 2022 to 11th September 2023. The sample size of 240 was determined using
- 112 the Kish Leslie and Fleiss formulae.
- 113 Study design and data collection procedure
- 114 The study used a cross sectional study design. Quantitative data was collected using a
- 115 questionnaire onto which socio-demographic information, anthropometry and relevant history

116 were captured.

117 Inclusion and exclusion criteria

118 We included all participants below 18 years, on a DTG based regimen for at least 6 months with

- 119 documented good adherence in the last 4 months and excluded those who had an acute illness, a
- 120 past history of hyperglycemia or if they declined to consent or assent.

121 Study variables

- 122 The dependent variable was hyperglycemia defined as a random plasma glucose concentration of
- $\geq 11.1 \text{ mmol/l} (200 \text{ mg/dl}) \text{ or an HbA1c of} > 6.5\% (15).$ Patients with prediabetic glycemic
- 124 levels were also considered to have hyperglycemia. This was determined by a random plasma
- 125 glucose of 7.8-11.0 mmol/L or an HBA1C of 5.7-6.4%.
- 126 Independent variables included patient factors like age, sex, current and pretreatment Body Mass
- 127 Index (BMI) for age z scores, Pre-existing comorbidities, Age at diagnosis of HIV, Age at ART
- 128 initiation, Use of other medications, WHO Stage, Duration on ART, Duration on DTG and most

129 recent viral load. Health system factors included Glycemic screening, patient Education on DTG

130 Adverse Events and Glycemic Monitoring

131 Data management and analysis

132 Data was entered into EpiData (v4.6) and exported to STATA version 17 for analysis. Univariate

133 analysis was done for socio-demographic and baseline clinical characteristics and was presented

134 in form of frequencies, proportions and means. A bivariate analysiss was performed to determine

- the association between the dependent and independent variables. Variables with p values <0.2
- 136 were considered for multivariate analysis. A logistic regression was then performed to determine
- 137 the statistical significance of the association between these variables and hyperglycemia. Factors
- 138 with P values <0.05 were considered statistically significant.

139 **Ethical consideration**

The study protocol was approved by the School of Medicine Research and Ethics Committee (SOMREC), reference number Mak-SOMREC-2022-405. Administrative clearance was further obtained from the hospital directors and research committees of Soroti and Lira RRHs. Parental consent was obtained for participants below 8 years while assent was obtained for participants 8 years and above and substantiated by a witness within the clinic. All consent was written and documented on a parental consent or assent form as applicable.

146 **Results**

147 **Participant Demographic and baseline clinical characteristics**

148 Data was analyzed for 240 participants. Mean age was 12.36 ± 3.76 years. Females accounted for

- 149 55.4% (n=133) and 71.7% (n=172) were over 10 years of age. Median age at HIV diagnosis was
- 150 24.06 (IQR, 1.33-46.79) months. Majority of participants, 202 (84.2%), had been on ART for more

- 151 than 5 years, only 37.9% (n=91) had been on a DTG-containing regimen for more than 2 years
- 152 while 68.8% (n=165) initiated ART before the age of five years s presented in **Table 1** below.
- 153 Table 1: Demographic and baseline clinical characteristics of study participants

Variable	Total n=240	Percentage (%)		
Age (Years)				
1-4	10	4.2		
5-10	58	24.2		
>10	172	71.7		
Sex				
Female	133	55.4		
Male	107	44.6		
Age at ART STAT (Years)				
0-4	165	68.8		
5-10	62	25.8		
>10	13	5.4		
Duration on ART(Years)				
<1	4	1.7		
1-5	34	14.2		
>5	202	84.2		
Duration on DTG				
<1	26	10.8		
1-2	123	51.3		
>2	91	37.9		
Baseline CD4				
<100 cells/mm ³	6	2.5		
100 <250 cells/mm ³	8	3.3		
250-500 cells/ mm ³	16	6.7		
>500 cells/ mm ³	37	15.4		
Unknown	173	72.1		
Baseline ART				
NVP based	128	53.3		
EFV based	60	25.0		
PI based	40	16.7		
DTG	12	5.0		
WHO Stage at ART initiation				
Stage I	177	73.8		
Stage II	29	12.1		
Stage III	26	10.8		
Stage IV	8	3.3		
BMI for age z scores at DTG initiation				
Normal	197	82.1		
Overweight	10	4.2		
Underweight	11	4.6		
Not assessed	22	9.1		
Abbreviations: NVP Nevirapine EFV Efav	irenz PI Protease Inhibitor			

- 154 Only 37.9% (n=67) had results for baseline CD4 counts, of which 5.8% (n=14) had a CD4 count
- below 250 cells/mm3. Approximately 53.3% (n=128) of the study participants initially received
- 156 Nevirapine as baseline ART, and only 5.0% (n=12) were initiated on a DTG-based regimen.
- 157 Significantly, 73.8% (n=177) of the participants were classified as WHO stage I at the initiation
- 158 of ART, however, upon the most recent WHO clinical staging, this percentage notably increased
- to 94.6%, highlighting substantial clinical improvement in the study population.

160 Recent clinical characteristics of study participants

- 161 Majority of clients, 92.1% (n=221), were still on a first-line ART regimen. Specifically, 62.9%
- 162 (n=151) of participants are on a Tenofovir-based ART drug combination as in *Table 2* below.
- 163 Table 2: Recent clinical characteristics of study participants

Variable	Total n=240	Percentage (%)
Current regimen line		
1st Line	221	92.1
2nd Line	17	7.1
3rd Line	2	0.8
Current ART Regimen		
ABC based	80	33.3
TDF Based	151	62.9
AZT Based	8	3.3
PI and NRTI based	1	0.4
Viral Load		
Suppressed	199	82.9
Non suppressed	38	15.8
Not done	3	1.3
Current BMI for age z scores		
Normal	205	85.4
Overweight	12	5.0
Underweight	23	9.6
Recent WHO stage		
Stage 1	227	94.6
Stage II	10	4.2
Stage III	2	0.8
Stage IV	1	0.4

- 165 Only 2 (0.9%) participants, have transitioned to a third-line ART regimen. It is noteworthy that
- 166 only 82.9% of the participants had achieved virological suppression, defined as having a viral load
- 167 less than 1000 copies/ml.
- 168 Additionally, 85.4% (n=205) of the participants had normal body mass index (BMI) for age z-
- scores and there were notably no significant changes in BMI for age z-scores between the
- 170 initiation of DTG and recent measurements.

171 Prevalence of Dolutegravir-related-hyperglycemia

- 172 A participant was considered to have hyperglycemia if either their RBS measurement was
- 173 greater than 7.8 mmol/L or their HbA1c level was equal to or greater than 5.7%. This inclusive
- 174 definition also encompassed the prediabetes state.
- 175 Overall, the findings revealed that 49 (20%) [95% CI 0.1506, 0.2578] study participants had
- 176 hyperglycemia. Notably, HbA1C levels varied from 3.5% 6.7%.
- 177 Among those diagnosed with hyperglycemia, HbA1c alone was responsible for identifying
- 178 hyperglycemia in the majority, with 46 (93.9%) participants diagnosed using this measure.
- 179 Conversely, only a small proportion, 3 (6.1%), were identified as hyperglycemic based on the
- 180 RBS measurement alone. Only two participants had diabetic range HbA1C levels.

181 Patient factors associated with DTG-related-hyperglycemia

- 182 At bivariate analysis for the clinical characteristics of study participants, age, duration on DTG
- and baseline CD4 had P values <0.2 and were considered for the multivariate analysis as shown
- 184 in **Table 3** below.

Variable	Hyperg	lycemia	Crude OR (95% CI)	P Value
	No	Yes	,	
	n=191 (80%)	n=49 (20%)		
Current regimen line				0.071*
1st Line	172(77.8)	49(22.2)	1	
2nd Line	17(100.0)	0(0.0)	0.1(0.01, 1.7)	0.110
3rd Line	2(100.0)	0(0.0)	0.7(0.03, 14.8)	0.817
Current ART Regimen				0.172*
ABC based	70(87.5)	10(12.5)	1	
TDF Based	114(75.5)	37(24.5)	2.2(1.04, 4.6)	0.038*
AZT Based	6(75.0)	2(25.0)	2.6(0.5, 12.7)	0.244
PI and NRTI based	1(100.0)	0(0.0)	2.2(0.1, 58.6)	0.629
Viral Load	. /	. /		0.308
Suppressed	155(77.9)	44(22.1)	1	
Non suppressed	33(86.8)	5(13.2)	0.6(0.2, 1.5)	0.257
Not done	3(100.0)	0(0.0)	-	
Current BMI for age z scores	· · /			0.791
Normal	165(80.5)	40(19.5)	1	
Overweight	8(66.7)	4(33.3)	2.2(0.7, 7.1)	0.205
Underweight	18(78.3)	5(21.7)	1.2(0.4, 3.3)	0.706
Total	165(80.5)	40(19.5)		
Recent WHO stage				0.854
Stage 1	180(79.3)	47(20.7)	1	
Stage II	8(80.0)	2(20.0)	1.1(0.3, 4.7)	0.880
Stage IV	2(100.0)	0(0.0)	0.8(0.04, 16.1)	0.860
Not staged	1(100.0)	0(0.0)	1.3(0.01, 31.6)	0.885
Herbal Remedies	()			0.129*
No	174(80.9)	41(19.1)	1	
Yes	17(68.0)	8(32.0)	2.0(0.8, 5.0)	0.114
History suggesting				0.001*
hyperglycemia				
Polyuria	3(100.0)	0(0.0)	-	
Polydipsia	0(0.0)	3(100.0)	-	
Polyphagia	0(0.0)	1(100.0)	-	
None	188(80.7)	45(19.3)	-	
Family History of HTN	~ /			0.035*
No	178(81.3)	41(18.7)	1	
Yes	13(61.9)	8(38.1)	2.7(1.1, 6.8)	0.034

185 Table 3: Patient factors associated with DTG-related-hyperglycemia

186 A subset of study participants, 25 (11.7%), reported a history of using herbal remedies and only

187 8 (32%) were found to have hyperglycemia. Majority of study participants 233 (97.1%) did not

188 have any history suggestive of hyperglycemia and only 21 (8.8%) had a family history of

189 hypertension.

- 190 At bivariate analysis, current regimen line, current ART regimen, history of use of herbal
- 191 remedies and family history of hypertension was considered for multivariate analysis.

192 Health system factors associated with DTG-related-hyperglycemia

- According to the study data, only 45(18.8%) participants had a baseline random blood sugar
- done at initiation of DTG while 169 (70.4%) had never received any form of glycemic
- 195 monitoring. The majority of participants, 60.4% had not received a health education talk on DTG
- 196 related adverse events and only 54.6% were aware of reporting avenues for DTG related adverse
- 197 events. This is summarized in *Table 4* below.

198 Table 4: Health System factors associated with DTG-related-hyperglycemia

Variable		Hyperglycemia		Crude OR (95% CI)	P value
	Total	No	Yes		
		n=191(80%)	n=49 (20%)		
Base line BGL at DTG Sta	art				
Not done	195(81.3)	147(75.4)	48(24.6)	1	
Normal	44(18.3)	43(97.7)	1(2.3)	0.1(0.01, 0.6)	0.008*
Elevated	1(0.4)	1(100.0)	0(0.0)	-	
BGL Monitoring on DTG					
Never	169(70.4)	125(74.0)	44(26.0)	1	
once	48(20.0)	43(89.6)	5(10.4)	0.4[0.1, 0.9]	0.033
More than once	23(9.6)	23(100.0)	0(0.0)	0.1[0.04, 1.01]	0.051
Health Education on DTC	G AEs				
No	145(60.4)	105(72.4)	40(27.6)	1	
Yes	95(39.6)	86(90.5)	9(9.5)	0.3[0.1, 0.6]	0.001*
Awareness of DTG AE					
reporting avenues					
No	109(45.4)	90(82.6)	19(17.4)	1	
Yes	131(54.6)	101(77.1)	30(22.9)	0.3(0.1, 0.6)	0.305
Abbreviations: BGL: Bloo	d glucose level	AE: Adverse ever	nts		

199 The bivariate analysis in this study showed that there were significant associations between

200 glycemic monitoring and health education talks on DTG side effects with the occurrence of

201 hyperglycemia. Participants who had their plasma glucose levels monitored at least once had a

lower likelihood of developing hyperglycemia, (OR 0.4, 95% CI, 0.1-0.9) P = 0.033.

- 203 Similarly participants who had received a health education talk on the side effects of DTG had a
- lower likelihood of developing hyperglycemia (OR 0.3, 95% CI, 0.1-0.6), P=0.001.

205 Multivariate analysis of factors associated with DTG-related-hyperglycemia

- 206 At multivariate analysis, only Health Education on Dolutegravir associated adverse events was
- 207 found to have a statistically significant association with developing DTG-related hyperglycemia
- as summarized in *Table 5* below.

209 Table 5: Multivariate analysis of factors associated with Dolutegravir-related-hyperglycemia

Variables	COR[95% conf. interval]	P-value	AOR[95% conf. interval]	P-values
Duration on DTG[Years]				
<1	1		1	
1-2	2.4[0.7, 7.8]	0.158	2.1[0.6, 7.3]	0.234
>2	1.3[0.4, 4.5]	0.707	1.2[0.3, 4.7]	0.748
Current ART Regimen				
ABC based	1		1	
TDF Based	2.2[1.04, 4.6]	0.038	2.1[0.9, 4.6]	0.073
AZT Based	2.6[0.5, 12.7]	0.244	3.4[0.6, 18.7]	0.153
PI and NRTI based	2.2[0.1, 58.6]	0.629	5.6[0.2, 170.8]	0.326
Family History of HTN				
No	1		1	
Yes	2.7[1.1, 6.8]	0.034	1.6[0.6, 4.2]	0.358
BGL Monitoring on DTG				
Never	1		1	
once	0.4[0.1, 0.9]	0.033	0.4[0.2, 1.2]	0.101
More than once	0.1[0.04, 1.01]	0.051	0.1[0.01, 1.7]	0.113
Health Education on DTG AEs				
No	1		1	
Yes	0.3[0.1, 0.6]	0.001	0.4[0.2, 0.9]	0.035

²¹⁰ Abbreviations: AEs, Adverse events HTN Hypertension ABC Abacavir TDF Tenofovir AZT Zidovudine PI

211 Protease Inhibitor

212 After adjusting for other factors, participants who had health education talks on DTG-related-

213 hyperglycemia were 60% less likely to develop hyperglycemia compared to those who did not

214 receive any (AOR 0.4, 95% CI, 0.2-0.9, P = 0.035).

215 **Discussion**

- 216 This cross-sectional study determined the prevalence and factors associated with Dolutegravir-
- 217 related hyperglycemia among children and adolescents in two regional referral hospitals in
- 218 Uganda. The study included a total of 240 participants from Soroti RRH and additional
- 219 participants from Lira Regional Referral Hospital.
- 220 Hyperglycemic status was determined based on elevated random blood sugar or glycated
- hemoglobin levels. The study suggested an association between the use of a Dolutegravir-
- 222 containing ART regimen and hyperglycemia.
- 223 The study findings reveal that among children and adolescents on a DTG-based ART regimen,
- the prevalence of hyperglycemia was 20%, indicating that approximately two out of every 10children were affected.
- Furthermore, the prevalence of prediabetes and diabetic range hyperglycemia was 17.9% and 2.1% respectively. This prevalence is higher compared to the estimated rates of prediabetes and diabetes in the broader African region, which is reported to be 8.6% and 3.3% respectively (16). The difference in prevalence could be attributed to the specific population studied (children and adolescents on DTG-based ART) who have an additional risk factor of HIV infection, which is known to be associated with an increased risk of hyperglycemia.
- Results from a similar study conducted in Botswana by Moverman *et al;*, showed the prevalence of prediabetes and diabetic range hyperglycemia in the general population of persons living with HIV to be 30% and 6% respectively(17). The lower prevalence in our study can be explained by the fact that the former study was conducted in a population of older adults who were over 40 years age and therefore had additional risk factors for hyperglycemia associated with older age.

237 It is important to highlight that there is currently no published data available on the prevalence of 238 DTG-related hyperglycemia specifically in the child and adolescent age group. Abera *et al*; in 239 2022 reported a prevalence of 14.7% among adult patients attending a tertiary hospital in 240 Ethiopia. The higher prevalence in our study could be attributed to the inclusion of prediabetic 241 HbA1C levels as part of the criteria for hyperglycemia in the current study, which was not 242 considered in the Ethiopian study. This suggests that prediabetic states may contribute to the 243 higher prevalence observed in the child and adolescent population. 244 In contrast, Odenyo et al; in 2020 reported a prevalence of 55.9% in their study conducted in an

adult population in a Kenyan hospital(18). These findings may be attributed to the presence of
additional risk factors in the adult age group like insulin resistance, impaired glucose tolerance,
or age-related changes in metabolism that predisposes them to an increased risk of developing
hyperglycemia.

Related studies include one by Bahamdain *et al;* in Arizona where 7% of adult study participants met the criteria for prediabetes 3-6 months after DTG initiation(19). However, in the current study, due to the cross-sectional study design, the survival time to developing prediabetes could not be determined. In addition, Namara *et al;* in their case control study in Uganda, reported that adults who had been previously exposed to a Dolutegravir-containing regimen had seven times higher odds of developing hyperglycemia compared to those with no history of exposure (20).

Dolutegravir has been postulated to cause hyperglycemia by a mechanism involving chelation of Magnesium which is critical for the action of viral integrase enzyme in the HIV replication cycle. These study findings should therefore be of great concern since current WHO and MoH-Uganda HIV care and treatment guidelines only emphasize DTG glycemic screening and monitoring for mainly adults over 45 years who are perceived to be at risk for hyperglycemia overlooking the

260 potential risk to children and adolescents which is probably based on an assumption that children 261 and adolescents are usually euglycemic. These findings thus suggest that the prevalence of 262 Dolutegravir-related hyperglycemia can vary across different populations and age groups. 263 At bivariate analysis, a number of factors were found to be associated with hyperglycemia and 264 these included a history of using a TDF based ART regimen, family history of hypertension and 265 history of health education on adverse events associated with DTG use. 266 Children and adolescents who received health education on the side effects of Dolutegravir were 267 less likely to develop hyperglycemia cOR 0.3 (p = 0.001). Furthermore, at multivariate analysis, 268 after adjusting for other factors, health education talks remained significantly protective against 269 DTG-related hyperglycemia, with (aOR) of 0.4 (p = 0.035). This could be attributed to the fact 270 that currently, facility based education sessions are also geared towards control of Non 271 communicable Diseases (NCDs) with emphasis on enhancement of lifestyle modifications 272 protective for diabetes and hypertension. 273 There has been a remarkable paradigm shift in the content of health education talks. Early at the 274 start of the HIV epidemic, health education talks were focused on stigma reduction, adherence 275 and disclosure however owing to the success of the ART program, PLHIV are living longer and 276 faced with higher risk for NCDs given the additional risk posed by the HIV infection and the anti

HIV drugs. The focus of health education sessions has had to include modalities for screeningand prevention of NCDs.

Fitch *et al;* 2006 in their study demonstrated that weekly counseling by a dietician with main emphasis on healthy eating, rather than weight loss, was associated with a significant reduction in blood pressure, waist circumference and HbA1c (21). In addition, endurance and resistance

282	exercises have also been shown to have positive effects on metabolic parameters in HIV infected
283	patients (22) therefore health education messages that highlight such lifestyle modifications are
284	protective for hyperglycemia.

285 Other studies have shown that effective health education improves knowledge, attitude, and

286 practices, particularly with regard to lifestyle modifications and dietary management,

287 culminating into better glycemic control that can slow down the progression of diabetes and

288 prevent downstream complications (23).

289 These findings thus highlight the importance of health education in reducing the risk of

290 hyperglycemia in individuals using DTG.

291 The study did not reveal any statistically significant association between hyperglycemia and sex,

BMI for age z scores, duration on Dolutegravir, WHO stage, baseline CD4 counts, and the use of

293 herbal drug remedies. These findings differ from previous studies that have reported associations

between these factors and Dolutegravir-related hyperglycemia. For example, Odenyo *et al*;

found that females were 1.6 times more likely to develop DTG-related hyperglycemia (18),

while Miiro *et al*; and Abera *et al*; reported that males were more likely to develop

hyperglycemia (24,25). Additionally, Odenyo et al; found that overweight patients were 1.7

times more likely to develop hyperglycemia. In terms of BMI for age z scores, the current study's

findings align with studies by Namara *et al;* and the GLUMED study in Kampala, which also did

300 not find a significant association between BMI and hyperglycemia (20,26). The duration on

301 Dolutegravir also did not show a statistically significant association with hyperglycemia in

302 contrast to the findings by Lamorde *et al;* in Uganda (5). Similarly, factors such as WHO stage,

303 baseline CD4 counts, and the use of herbal drug remedies also did not demonstrate a significant

304 association with hyperglycemia in the current study.

305 Strength of the study

- 306 This is among the few studies in Uganda to investigate the prevalence of DTG-related
- 307 hyperglycemia among children and adolescents making this study valuable in addressing a
- 308 critical knowledge gap that highlights the potential risk of hyperglycemia in younger age groups.
- 309 Additionally, the inclusion of HbA1c as a diagnostic criterion for hyperglycemia adds to the
- 310 robustness of the study since HbA1c is a reliable indicator of long-term glucose control and
- 311 provides a comprehensive assessment of glycemic status.

312 Study limitations

The study sites were hospitals based in peri-urban settings posing limitations in generalizability to other settings especially the urban rich who are predisposed to cofounders for hyperglycemia like obesity and sedentary lifestyles.

316 The cross-sectional study design limits ability to establish a causal relationship between

317 hyperglycemia and DTG use. The absence of baseline plasma glucose measurements also

318 hinders determination of the temporal relationship between hyperglycemia and DTG use.

319 The use of consecutive enrollment rather than random sampling and the limitation to participants

320 attending the clinic on a specific day introduces selection bias, potentially affecting the

321 representativeness of the sample.

322 Additionally, the study's sample size was not adequately powered, which may have influenced

323 the study results. The sample size calculation based on prevalence estimates from the adult

324 population may not accurately reflect the prevalence of hyperglycemia in children and

325 adolescents leading to an overestimation or underestimation of the required sample size,

- 326 potentially affecting the precision and validity of the study findings.
- 327 The time period for the measurement of Random blood sugar after a meal was not standardized
- 328 and therefore could have posted a falsely elevated plasma glucose level.
- 329 The study outcome which was hyperglycemia could have been over or under classified
- 330 subsequently giving a relatively higher or lower prevalence respectively.

331 Conclusions

332 The prevalence of Dolutegravir-related-hyperglycemia is high occurring in every 2 in 10 children

and adolescents. The findings highlight the need for increased attention to glycemic screening

and monitoring in this population. Health education talks on DTG adverse events were found to

be protective against hyperglycemia underscoring the need to develop comprehensive health

336 education messages that address DTG related complications and ensure optimal care for children

and adolescents on Dolutegravir-based ART regimens.

338 **Recommendations**

339 Based on the study findings, there should be advocacy for updates in HIV treatment guidelines to

340 include specific recommendations for glycemic screening and monitoring for children and

- 341 adolescents on Dolutegravir-based ART regimens.
- 342 The use of glycated hemoglobin (HbA1c) tests, for persons on a DTG based regimen should be
- 343 supported given its accuracy in monitoring glycemic control over a longer duration.
- 344 Routine Glycemic screening and monitoring is recommended for children and adolescents on
- 345 Dolutegravir-based ART regimens to support early detection and management of hyperglycemia.

346	Health Education programs for children, adolescents, and their caregivers should routinely focus
347	on the potential side effects of Dolutegravir, including hyperglycemia with emphasis on the
348	importance of lifestyle modifications, such as healthy eating habits and regular physical activity.
349	To conduct longitudinal studies to investigate the long-term implications of Dolutegravir-related
350	hyperglycemia in children and adolescents while evaluating the progression of hyperglycemia,
351	its impact on metabolic health, and the effectiveness of different management strategies.
352	Acknowledgements
353	The authors would like to acknowledge the contribution of Ambrose Okibure for support in the
354	statistical analysis and all the lecturers in the Department of Paediatrics and Child health,
355	Makerere University for their insightful input from concept development to completion of the
356	manuscript. We also appreciate Dr. Ben Watmon and Dr. Nathan Onyachi for providing
357	clearance to conduct the study in Soroti and Lira RRHs.
358	
359	
360	
361	
362	
363	
364	
365	

366 References

- 367 1. The World Health Organisation. Statement on DTG - Geneva 18 May 2018. Who. 2018;
- 368 Moore CL, Turkova A, Mujuru H, Kekitiinwa A, Lugemwa A, Kitvo CM, et al. ODYSSEY 2.
- 369 clinical trial design: a randomised global study to evaluate the efficacy and safety of dolutegravir-
- 370 based antiretroviral therapy in HIV-positive children, with nested pharmacokinetic sub-studies to
- 371 evaluate pragmatic WHO-weight-band based doluteg. BMC Infect Dis. 2021;
- 372 3. McLaughlin M, Walsh S, Galvin S. Dolutegravir-induced hyperglycaemia in a patient living with 373 HIV. Journal of Antimicrobial Chemotherapy. 2018.
- 374 4. Kamal P, Sharma S. SUN-187 Dolutegravir Causing Diabetes. J Endocr Soc.
- 375 2019;3(Supplement 1).
- 376 5. Lamorde M, Atwiine M, Owarwo NC, Ddungu A, Laker EO, Mubiru F, et al. Dolutegravir-377 associated hyperglycaemia in patients with HIV. The Lancet HIV. 2020.
- 378 6. Tosur M, Viau-Colindres J, Astudillo M, Redondo MJ, Lyons SK. Medication-induced 379
- hyperglycemia: Pediatric perspective. BMJ Open Diabetes Research and Care. 2020.
- 380 7. Song IH, Zong J, Borland J, Jerva F, Wynne B, Zamek-Gliszczynski MJ, et al. The effect of
- 381 dolutegravir on the pharmacokinetics of metformin in healthy subjects. J Acquir Immune Defic 382 Syndr. 2016;
- 383 8. Mercadel CJ, Skelley JW, Kyle JA, Elmore LK. Dolutegravir: An integrase strand transfer

384 inhibitor for the treatment of human immunodeficiency virus I in adults. J Pharm Technol. 2014;

- 385 Mooren FC, Krüger K, Völker K, Golf SW, Wadepuhl M, Kraus A. Oral magnesium 9.
- 386 supplementation reduces insulin resistance in non-diabetic subjects - a double-blind, placebo-
- 387 controlled, randomized trial. Diabetes, Obesity and Metabolism. 2011.
- 388 10. Paolisso G, Scheen A, D'Onofrio F, Lefèbvre P. Magnesium and glucose homeostasis. 389 Diabetologia. 1990.
- 390 11. Hailu W, Tesfaye T, Tadesse A. Hyperglycemia after dolutegravir-based antiretroviral therapy. Int

- 391 Med Case Rep J. 2021;
- 392 12. Marcovecchio ML. Complications of acute and chronic hyperglycemia. US Endocrinology. 2017.
- 393 13. Dobrica E, Gaman MA, Cozma MA, Gaman AM, Diaconu CC. MACROVASCULAR AND
- 394 MICROVASCULAR COMPLICATIONS IN TYPE 2 DIABETES MELLITUS. J Hypertens.
- 395 2019;
- 396 14. Ministry of Health. Consolidated Guidelines for Prevention and Treatment of HIV in Uganda
- 397 Ministry of Health Knowledge Management Portal. 2018;(February). Available from:
- 398 http://library.health.go.ug/publications/hivaids/consolidated-guidelines-prevention-and-treatment 399 hiv-uganda
- 400 15. Sundberg F, Barnard K, Cato A, de Beaufort C, DiMeglio LA, Dooley G, et al. ISPAD Guidelines.
 401 Managing diabetes in preschool children. Pediatr Diabetes. 2017;
- 402 16. International Diabetes Federation. Diabetes Atlas, 2019. 9 th ed. Brussels, Belgium: IDF, 2019.
 403 2019.
- 404 17. Hirsch-Moverman Y, Howard AA, Mantell JE, Bongomin P, Wu Y, El-Sadr WM, et al. High
- 405 prevalence of pre-diabetes among people living with HIV in a high TB burden setting.
- 406 International Journal of Tuberculosis and Lung Disease. 2020.
- 40718.Odenyo JA, Pharm B. Prevalence of Dolutegravir Associated Hyperglycemia and Its Covariates
- 408 Among Persons Living With Hiv on Treatment At Kenyatta National Hospital. 2020;21(1):1–13.
- 409 19. Bahamdain FO. Effect of dolutegravir on plasma glucose among human immunodeficiency virus
 410 patients in a community health center setting. Int J Community Med Public Heal. 2022;
- 411 20. Namara D, Schwartz JI, Tusubira AK, McFarland W, Birungi C, Semitala FC, et al. The risk of
- 412 hyperglycaemia associated with the use of dolutegravir among adults living with HIV in Kampala,
- 413 Uganda: a case-control study. Lancet Glob Heal. 2022;10.
- 414 21. Fitch K V., Anderson EJ, Hubbard JL, Carpenter SJ, Waddell WR, Caliendo AM, et al. Effects of
 415 a lifestyle modification program in HIV-infected patients with the metabolic syndrome. AIDS.

416 2006;

- 417 22. Robinson FP, Quinn LT, Rimmer JH. Effects of High-Intensity Endurance and Resistance
- 418 Exercise on HIV Metabolic Abnormalities: A Pilot Study. Biol Res Nurs. 2007;
- 419 23. Chawla SS, Kaur S, Bharti A, Garg R, Kaur M, Soin D, et al. Impact of health education on
- 420 knowledge, attitude, practices and glycemic control in type 2 diabetes mellitus. J Fam Med Prim
 421 Care. 2019;
- 422 24. C Miiro, GJ Imodia MM. Relationship between hyperglycemia and dolutegravir based HAART

423 and the associated factors at Mbale regional referral hospital: A case-control study. 2022.

- 424 25. Abera MA. Dolutegravir-Associated Hyperglycemia in People Living with Human Immune-
- 425 Deciency Virus: A Prospective Cohort Study. Res Sq. 2023;
- 426 26. Mulindwa F, Castelnuovo B, Brusselaers N, Bollinger R, Rhein J, Edrisa M, et al. Blood glucose
- 427 trajectories and incidence of diabetes mellitus in Ugandan people living with HIV initiated on

dolutegravir. AIDS Res Ther. 2023;